Current News

PRESS RELEASE

Accera, Inc. Announces Dr. Gunnar Weikert Elected to Board of Directors

Broomfield, CO, July 27, 2009 – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today that Gunnar Weikert, M.D., Ph.D., has been elected to its board of directors.

Dr. Weikert is the Chairman, CEO and Founder of Inventages Venture Capital. Prior to the founding of Inventages, he had more than 10 years experience in a broad spectrum of executive functions in the pharmaceutical industry culminating as senior vice president and global head for life sciences transactions at Bayer AG. While at Bayer, he oversaw venture investments in technology companies and collaborations representing some of the largest transactions involving large pharmaceutical and biotechnology companies in the late 1990s.

Dr. Weikert received his M.D. from the University of Düsseldorf and his Ph.D. in the field of metabolism from the Diabetes Research Center in Germany. He also holds an MBA.

“We are delighted to welcome Dr. Weikert to our board of directors,” said Steve Orndorff, Ph.D., Accera’s founder and CEO. “Gunnar has an outstanding track record in venture investing throughout the world and has a keen sense for innovative product concepts that are revolutionizing human health and well-being.”

Dr. Orndorff continued, “With Accera’s recent launch of Axona™, a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease, Dr. Weikert’s experience and expert guidance will be invaluable.”

Dr. Weikert replaces Dr. Robert Schier, who resigned from Accera’s board in June.

About Accera, Inc..
Accera, Inc., a privately held biotechnology company, discovers and develops therapeutic breakthroughs in central nervous systems disorders. Accera’s novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy source for the brain.

For more information about Accera, please visit www.accerapharma.com.

###

Contacts: